Alexandra Mayer-Da-Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexandra Mayer-Da-Silva has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Silvia Rossi
Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy
4 shared publications - Annalisa Trama
Evaluative Epidemiology Unit, Fondazione IRCSS Istituto Nazionale dei Tumori, Milan, Italy
2 shared publications - Claudia Vener
Epidemiology and Prevention Unit, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
2 shared publications - Damien Bennett
Northern Ireland Cancer Registry (NICR), Queens University Belfast, Centre for Public Health, Mulhouse Building, Belfast, Northern Ireland, UK
2 shared publications - Fabio Didonè
Evaluative Epidemiology Unit, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale Dei Tumori, 20133 Milan, Italy
2 shared publications - Francesco Cerza
Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy
2 shared publications
Latest Publications
- 19 October 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 231, 116061
Skin melanoma survival is improving in Europe but regional differences persist: Results of the EUROCARE-6 study
- 19 October 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 231, 116061
Skin melanoma survival is improving in Europe but regional differences persist: Results of the EUROCARE-6 study
- Open Access
- 28 July 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 227, 115661
Survival of European adolescents and young adults diagnosed with central nervous system tumours and comparison with younger and older age groups: EUROCARE-6 results
- 28 July 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 227, 115661
Open AccessSurvival of European adolescents and young adults diagnosed with central nervous system tumours and comparison with younger and older age groups: EUROCARE-6 results
- Open Access
- 11 June 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 226, 115535
Comparative analysis of 5-year relative survival in adolescents and young adults with cancer relative to both children and adults in Europe (EUROCARE-6): Results from a population-based study
- 11 June 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 226, 115535
Open AccessComparative analysis of 5-year relative survival in adolescents and young adults with cancer relative to both children and adults in Europe (EUROCARE-6): Results from a population-based study
- Open Access
- 19 April 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 222, 115443
Estimating cure and risk of death from other causes of adolescent and young adult cancer patients in Europe
- 19 April 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 222, 115443
Open AccessEstimating cure and risk of death from other causes of adolescent and young adult cancer patients in Europe
- 10 November 2023
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 22 (1) , e170-e177.e1
Epidemiology, Management, and Survival Outcomes of Germ Cell Cancer in Southern Portugal: A Population-Based Study (2008-2012)
- 10 November 2023
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 22 (1) , e170-e177.e1
Epidemiology, Management, and Survival Outcomes of Germ Cell Cancer in Southern Portugal: A Population-Based Study (2008-2012)
- Open Access
- 5 June 2023
- Published by Ubiquity Press, Ltd. in Annals of Global Health
- Vol. 89 (1) , 39
The Effect of Timeliness of Care on Lung Cancer Survival – A Population-Based Approach
Background: Timeliness of care is an important dimension of healthcare quality but it’s unclear whether it improves clinical outcomes in lung cancer (LC) patients. Objectives: This study aims to analyze treatment patterns, time-to-treatment (TTT) and the impact of treatment timeliness (TT) in overall survival (OS) of patients diagnosed with LC in 2009–2014 in a population-based registry from Southern Portugal. Materials and Methods: We estimated median TTT for overall population, treatment type and stage. The impact of treatment and TT on five-year OS was analyzed using the Kaplan-Meier method and Cox regression modelling to determine the hazard ratio (HR) of death associated with treatment and TT. Results: From the 11,308 cases diagnosed, 61.7% received treatment. Treatment rate decreased with increasing stage from 88% in stage I to 66.1% in stage IV. Overall median TTT was 49 days (IQR: 28–88) and 43.3% received TT. Surgery had a longer TTT than radiotherapy and systemic treatment. Patients in earlier stages had lower TT rates and longer TTT compared to more advanced, 24.7% and 80 days in stage I versus 51.3% and 42 days in stage IV (p < 0.0001). OS was 14.9% for total population and 19.6% and 7.1% for patients with and without treatment registered, respectively. TT had no observed impact on OS for stages I/II but a negative effect for stages III/IV. Relative to treated, the adjusted mortality risk was higher in untreated patients (HR = 2.240; 95%CI: 2.293–2.553). Contrary to treatment, TT had a negative impact on survival, with 11.3% in timely vs. 21.5% in untimely treated. Compared to untimely treated, the risk of death in TT patients was 46.6% higher (HR = 1.465; 95%CI: 1.381–1.555). Conclusions: LC survival is highly dependent on early diagnosis and adequate treatment. Time-to-treatment was longer than recommended for all treatment types but particularly for surgery. Overall TT results were paradoxical, as better survival was observed in patients untimely treated. The factors associated with TT were not possible to analyze and its impact on patient outcomes remains unclear. However, it is important to assess quality-of-care to improved LC management.
- 5 June 2023
- Published by Ubiquity Press, Ltd. in Annals of Global Health
- Vol. 89 (1) , 39
Open AccessThe Effect of Timeliness of Care on Lung Cancer Survival – A Population-Based Approach
Background: Timeliness of care is an important dimension of healthcare quality but it’s unclear whether it improves clinical outcomes in lung cancer (LC) patients. Objectives: This study aims to analyze treatment patterns, time-to-treatment (TTT) and the impact of treatment timeliness (TT) in overall survival (OS) of patients diagnosed with LC in 2009–2014 in a population-based registry from Southern Portugal. Materials and Methods: We estimated median TTT for overall population, treatment type and stage. The impact of treatment and TT on five-year OS was analyzed using the Kaplan-Meier method and Cox regression modelling to determine the hazard ratio (HR) of death associated with treatment and TT. Results: From the 11,308 cases diagnosed, 61.7% received treatment. Treatment rate decreased with increasing stage from 88% in stage I to 66.1% in stage IV. Overall median TTT was 49 days (IQR: 28–88) and 43.3% received TT. Surgery had a longer TTT than radiotherapy and systemic treatment. Patients in earlier stages had lower TT rates and longer TTT compared to more advanced, 24.7% and 80 days in stage I versus 51.3% and 42 days in stage IV (p < 0.0001). OS was 14.9% for total population and 19.6% and 7.1% for patients with and without treatment registered, respectively. TT had no observed impact on OS for stages I/II but a negative effect for stages III/IV. Relative to treated, the adjusted mortality risk was higher in untreated patients (HR = 2.240; 95%CI: 2.293–2.553). Contrary to treatment, TT had a negative impact on survival, with 11.3% in timely vs. 21.5% in untimely treated. Compared to untimely treated, the risk of death in TT patients was 46.6% higher (HR = 1.465; 95%CI: 1.381–1.555). Conclusions: LC survival is highly dependent on early diagnosis and adequate treatment. Time-to-treatment was longer than recommended for all treatment types but particularly for surgery. Overall TT results were paradoxical, as better survival was observed in patients untimely treated. The factors associated with TT were not possible to analyze and its impact on patient outcomes remains unclear. However, it is important to assess quality-of-care to improved LC management.
- Open Access
- 8 February 2022
- Published by Elsevier in The Breast
- Vol. 62, 135-143
Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study
- 8 February 2022
- Published by Elsevier in The Breast
- Vol. 62, 135-143
Open AccessReal-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study